158 related articles for article (PubMed ID: 577895)
1. Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection.
Bleyer WA; Dedrick RL
Cancer Treat Rep; 1977 Jul; 61(4):703-8. PubMed ID: 577895
[TBL] [Abstract][Full Text] [Related]
2. Probenecid inhibition of methotrexate-cerebrospinal fluid pharmacokinetics in dogs.
Ramu A; Fusner JE; Blaschke T; Glaubiger DL
Cancer Treat Rep; 1978 Oct; 62(10):1465-70. PubMed ID: 581360
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?
Niemann A; Mühlisch J; Frühwald MC; Gerss J; Hempel G; Boos J
Ther Drug Monit; 2010 Aug; 32(4):467-75. PubMed ID: 20571463
[TBL] [Abstract][Full Text] [Related]
4. Active transport of methotrexate from cerebrospinal fluid in humans.
Bode U; Magrath IT; Bleyer WA; Poplack DG; Glaubiger DL
Cancer Res; 1980 Jul; 40(7):2184-7. PubMed ID: 7388786
[TBL] [Abstract][Full Text] [Related]
5. High-dose methotrexate in acute lymphocytic leukemia.
Freeman AI; Wang JJ; Sinks LF
Cancer Treat Rep; 1977 Jul; 61(4):727-31. PubMed ID: 267510
[TBL] [Abstract][Full Text] [Related]
6. A pharmacokinetic model for predicting the concentration of methotrexate in plasma subsequent to intrathecal injection.
Ramu A; Fusner JE
Isr J Med Sci; 1979 Jun; 15(6):494-9. PubMed ID: 582316
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacokinetics of intrathecal chemotherapy and clinical problems].
Fujimoto T
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1536-42. PubMed ID: 6433796
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics.
Bleyer AW
Cancer Treat Rep; 1977 Nov; 61(8):1419-25. PubMed ID: 579164
[TBL] [Abstract][Full Text] [Related]
9. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma.
Pitman SW; Frei E
Cancer Treat Rep; 1977 Jul; 61(4):695-701. PubMed ID: 18282
[TBL] [Abstract][Full Text] [Related]
10. Methotrexate-associated alterations of the folate and methyl-transfer pathway in the CSF of ALL patients with and without symptoms of neurotoxicity.
Vezmar S; Schüsseler P; Becker A; Bode U; Jaehde U
Pediatr Blood Cancer; 2009 Jan; 52(1):26-32. PubMed ID: 19006245
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections.
Shapiro WR; Young DF; Mehta BM
N Engl J Med; 1975 Jul; 293(4):161-6. PubMed ID: 806016
[TBL] [Abstract][Full Text] [Related]
12. A primate model for study of methotrexate pharmacokinetics in the central nervous system.
Poplack DG; Bleyer WA; Wood JH; Kostolich M; Savitch JL; Ommaya AK
Cancer Res; 1977 Jul; 37(7 Pt 1):1982-5. PubMed ID: 405092
[TBL] [Abstract][Full Text] [Related]
13. Comparative effects of citrovorum factor and carboxypeptidase G1 on cerebrospinal fluid-methotrexate pharmacokinetics.
Abelson HT; Ensminger W; Rosowsky A; Uren J
Cancer Treat Rep; 1978 Oct; 62(10):1549-52. PubMed ID: 309355
[TBL] [Abstract][Full Text] [Related]
14. Age-related pharmacokinetics of high-dose methotrexate in patients with osteosarcoma.
Wang YM; Sutow WW; Romsdahl MM; Perez C
Cancer Treat Rep; 1979 Mar; 63(3):405-10. PubMed ID: 284845
[TBL] [Abstract][Full Text] [Related]
15. High-dose methotrexate: pharmacokinetics in children and young adults.
Raude E; Oellerich M; Weinel P; Freund M; Schrappe M; Riehm H; Poliwoda H
Int J Clin Pharmacol Ther Toxicol; 1988 Jul; 26(7):364-70. PubMed ID: 3209285
[TBL] [Abstract][Full Text] [Related]
16. Correlation of cerebrospinal fluid beta-glucuronidase activity with plasma methotrexate concentrations in leukemic children receiving high-dose methotrexate.
Vlacha V; Eliopoulou M; Haidas S; Beratis NG
Pediatr Blood Cancer; 2004 Apr; 42(4):350-6. PubMed ID: 14966832
[TBL] [Abstract][Full Text] [Related]
17. [Cerebrospinal fluid methotrexate level in children treated with medium-high and high doses of the drug].
Wysocki M; Balcar-Boroń A; Krzyzanowski M; Szadujkis-Szadurski L; Ozyński T; Nowaczyk-Michalak A
Acta Haematol Pol; 1992; 23(3):185-90. PubMed ID: 1492543
[TBL] [Abstract][Full Text] [Related]
18. Effect of activated charcoal on the pharmacokinetics of high-dose methotrexate.
Gadgil SD; Damle SR; Advani SH; Vaidya AB
Cancer Treat Rep; 1982 May; 66(5):1169-71. PubMed ID: 7083219
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate.
Breithaupt H; Küenzlen E
Cancer Treat Rep; 1982 Sep; 66(9):1733-41. PubMed ID: 6956440
[TBL] [Abstract][Full Text] [Related]
20. Intrathecal methotrexate-induced neurotoxicities.
Nelson RW; Frank JT
Am J Hosp Pharm; 1981 Jan; 38(1):65-8. PubMed ID: 7011005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
